OBR Daily Commentary

forumImage

CMS Revisits Biosimilar Payment Policy: Industry Comments Signal Expected Changes

(Regulatory Focus) Oct 30, 2017 - A tweak to a Centers for Medicare and Medicaid Systems (CMS) billing code system that could come later this week would have a big impact in making US biosimilars more competitive with their reference products.

Read Article arrow

Winston Wong, PharmD (Posted: November 02, 2017)

quotesA change is needed. Currently, there is no incentive to use a biosimilar. End of Story.quotes

Add Comment 1 Comment
forumImage

CVS Bid For Aetna: A $66 Billion Bet On Cutting Drug Costs

(Reuters) Oct 29, 2017 - The proposed merger between U.S. pharmacy operator CVS Health Corp and No. 3 health insurer Aetna Inc represents a $66 billion bet that insurers can drive down high U.S. drug prices by cutting out the middleman.

Read Article arrow

Winston Wong, PharmD (Posted: November 02, 2017)

quotesThere is one subtle, but very real difference in the CVS/Aetna combination when comparing to Anthem, Humana, and UHC. In the latter, the Healthplan owns and drives the PBM. In the former, CVS is purchasing Aetna, so the tides are turned opposite. Should lead to an interesting model development process. quotes

Add Comment 1 Comment
forumImage

Tracking the Cost of Gene Therapy

(MIT Technology Review) Oct 24, 2017 - Drug companies have attached astronomical prices to these narrowly targeted treatments. In fact, the prices are so high that one has already been pulled from the market in Europe, and the other has struggled to attract patients. But a treatment approved last week could change the equation.

Read Article arrow

Winston Wong, PharmD (Posted: November 02, 2017)

quotesThere is no doubt in my mind that pre-certification criteria will become more precise in identifying patients in where there therapies will be used. In the appropriate patient, payers will have a hard time denying coverage.. The trick is to find the appropriate patient. in some respects, it is no different than what we see today with other classes e.g. PCSK9's, but the stakes are higher. We can approve many PCSK9 patient for each CAR-T patient. On the other hand, we will probably see a more definite positive outcome with the CAR-T. Such a dilemma quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...